Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 3/20 | 0.35 |
| ▸ | CES1 | P23141 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19101609 | 0.81 | TSHR (0.32) | AKT1ATMCES1ALDH1A1TSHR | |
| SCHEMBL20625867 | 0.81 | MEN1 (0.32) | AKT1ATMMAPK1MEN1KMT2A | |
| SCHEMBL22071895 | 0.81 | LMNA (0.36) | AKT1ATMCES2CES1ALDH1A1 | |
| SCHEMBL21746859 | 0.81 | CES2 (0.33) | AKT1ATMCES2CES1ALDH1A1 | |
| SCHEMBL20653559 | 0.81 | MAOA (0.34) | AKT1ATM | |
| SCHEMBL21253891 | 0.79 | AKT1 (0.37) | AKT1ATMCES2CES1ALDH1A1 | |
| SCHEMBL19046658 | 0.79 | AKT1 (0.37) | AKT1ALDH1A1TSHRDAONAPRT | |
| SCHEMBL23183270 | 0.79 | ATM (0.41) | AKT1ATMCES2CES1ALDH1A1 | |
| SCHEMBL22988641 | 0.79 | KMT2A (0.37) | AKT1ATMCES2CES1ALDH1A1 | |
| SCHEMBL24975608 | 0.79 | AKT1 (0.33) | AKT1ATMCES2CES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022104348-A1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-19 | — | — | WO | disclosed |
| WO-2021057264-A1 | COMPOUND, PHOTOELECTRIC CONVERSION DEVICE, AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-2477999-B1 | FORMULATIONS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2019-01-23 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | AKT1 4770/4885ATM 3760/4885CES2 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.